Shots:

• The triple combination study- TRIFECTA involves the assessing of TAVO- Epacadostat & Keytruda vs Keytruda as monothx/keytruda + epacadostat as combination therapy in 35 patients with squamous cell carcinoma head and neck (SCCHN) cancer- with its 1EP as overall response rate (ORR) by RECIST v1.1 
• The TRIFECTA study will be conducted by UCSF Helen Diller Family Comprehensive Cancer Center- with its expected result as improvement in anti-PD-1 monotherapy durable remission response rate of 13-16%. The cost of the trial will be shared with Merck and Incyte Corporation
• TAVO (tavokinogene telseplasmid) enables intra tumoral delivery of DNA-based IL-12 targeting tumor cells. Epacadostat is an IDO inhibitor- enables the T-Cell modulation. Keytruda (pembrolizumab) is a mAb blocking the interaction between PD-1 and its ligands- PD-L1 and PD-L2 and activates the T lymphocytes

Ref: OncoSec | Image: Happy Hour Headshot